Street Calls of the Week
HOUSTON - Nutex Health Inc. (NASDAQ:NUTX), a healthcare company that has delivered an impressive 203% return year-to-date, announced Monday the appointment of Wesley Bamburg as its new Chief Operating Officer, effective October 13, 2025.
Bamburg, who brings 20 years of healthcare industry experience, currently serves as Chief Operating Officer for HCA Houston Healthcare North Cypress, a position he has held since July 2024. Previously, he was Chief Operating Officer at HCA Houston Healthcare Medical Center from 2019 to 2024. He joins Nutex Health at a time when the company demonstrates strong financial health, with InvestingPro analysis showing liquid assets exceeding short-term obligations and robust cash flows covering interest payments.
The executive began his career with HCA Healthcare in 2013 as Vice President of Payor Contracting & Alignment for the Gulf Coast Division. His earlier career included leadership roles in managed care, network operations, and physician alignment across 11 states.
Bamburg holds a Bachelor of Science in Healthcare Administration from Southwestern Oklahoma State University and an MBA from Oklahoma City University. He is board-certified in healthcare management and is a Fellow of the American College of Healthcare Executives.
"I am excited to contribute to the company’s dynamic growth and work alongside Dr. Vo and the entire team to shape the future of community-based hospital care," Bamburg said in the press release.
Nutex Health, headquartered in Houston, operates 24 healthcare facilities across 11 states through its Hospital Division, which includes micro-hospitals, specialty hospitals, and hospital outpatient departments. The company also manages provider networks through its Population Health Management division.
The physician-led healthcare delivery system trades on the Nasdaq under the ticker NUTX.
In other recent news, Newtek Health reported significant growth in its Q2 2025 earnings, with total revenue reaching $244 million, marking a 220% increase from the previous year. The company also noted a substantial rise in adjusted EBITDA and cash collections, attributing this growth to strategic investments in hospital developments and AI initiatives. In contrast, Nutex Health disclosed a securities class action lawsuit filed against the company and certain executives in the United States District Court for the Southern District of Texas. The complaint, based on a recent short seller report, seeks unspecified damages and names Nutex Health’s top executives as defendants. Additionally, Nutex Health appointed Michael L. Reed as the lead independent director of its board. Mr. Reed, who has been a board member since April 2022, will facilitate communication between independent directors and company management. These developments reflect the ongoing changes and challenges faced by Nutex Health and Newtek Health.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.